Journal ArticleOpen Access
Rifampin Drug Resistance Tests for Tuberculosis: Challenging the Gold Standard
Authors
Author Affiliations
International Union Against Tuberculosis and Lung Disease, Instituut voor Tropische Geneeskunde, Damien Foundation, Programme National Multisectoriel de Lutte contre le sida
Published InJournal of Clinical Microbiology
Year2013
Citations244
Abstract
The rapid diagnosis of rifampin resistance is hampered by a reported insufficient specificity of molecular techniques for detection of rpoB mutations. Our objective for this study was to document the prevalence and prognostic value of rpoB mutations with unclear phenotypic resistance. The study design entailed sequencing directly from sputum of first failure or relapse patients without phenotypic selection and comparison of the standard retreatment regimen outcome, according to the mutation present. We found that among all rpoB mutations, the best-documented "disputed" rifampin resistance mutations (511Pro, 516Tyr, 526Asn, 526Leu, 533Pro, and 572Phe) made up 13.1% and 10.6% of all mutations in strains from Bangladesh and Kinshasa, respectively. Except for the 511Pro and 526Asn mutations, most of these strains with disputed mutations…
View at Publisher
BORR does not host full-text PDFs. The button above takes you to the original publisher.